ADDvise converts loan of 5 MSEK to B-shares

28-10-2016   Non-regulatory press release
  • The subscription price amounts to 1.82 SEK per share based on a VWAP.
  • The issue provides ADDvise with approximately 5.1 MSEK.
  • The reason for deviation from the shareholders preferential rights and the motives for the share issue is to repay debt and thereby strengthen the capital structure of the Company.
  • The issue involves a dilution of approximately 9.0 percent of the capital and approximately 2.8 percent of the votes in the Company
  • The issue increases the number of shares of series B in the Company from 20 813 208 to 23 626 395 shares.
  • The company’s total number of outstanding shares increases from 28 432 647 shares to a total of 31 245 834 shares, divided between 7 619 439 class A and 23 626 395 B shares.
  • The share issue increases the share capital by 281 319 SEK, from 2 843 265 to 3 124 583 SEK and increase the number of voting rights from 9 700 760 to 9 982 078 votes.  

 

For further information, please contact:

Rikard Akhtarzand, CEO, +46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

www.addvisegroup.se

 

Important information:

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on October 28, 2016 at 08:30 CET.

 

About ADDvise Group AB

ADDvise Group AB (publ) is an expansive group which through its subsidiaries IM-Medico Svenska AB, KEBO Inredningar Sverige AB, ADDvise Tillquist AB, LabRum AB, Sonesta Medical AB, Sonesta Medical Inc and Surgical Tables Inc offers comprehensive solutions in the form of products and services to healthcare and research facilities. ADDvise Group's customers are located in both the private and public sectors. The Company's share is listed on First North Premier and Mangold Fondkommission AB, +46 8-503015 50, is the company's Certified Adviser and liquidity provider.

 

Latest press releases

ADDvise Group’s nomination committee for the Annual General Meeting 2022

Regulatory

In accordance with the resolution at the 2021 annual general meeting of ADDvise Group AB, the nomination committee for the annual general meeting 2022 shall be composed of representatives of the three largest shareholders by votes listed in the shareholders’ register, which is maintained by Euroclear Sweden as of 30 June 2021, and the chairman…

ADDvise Group’s reporting dates 2022

Regulatory

Year-End Report 2021 (Jan-Dec)                                 2022-02-24 Last day for shareholders to request                            2022-03-18 an item to be included to the agenda of the Annual General Meeting Interim Report (Jan-March 2022)                       …

On account of the difference in price movements in ADDvise Group’s shares

Regulatory

ADDvise Group AB (publ) (“ADDvise” and the “Company”) notes positive price movements in the Company's shares. ADDvise's share of series A carries one vote and share of series B carries one tenth of a vote, and besides this difference, the Company is not aware of any information concerning the Company which explains the difference between…

ADDvise updates long-term financial goals

Regulatory

ADDvise Group AB raises its long-term EBITDA financial target from 15% to 20%. ADDvise also raises its long-term revenue growth target from 20% to 25%. Other long-term financial goals remain unchanged. For the financial year 2022, on a pro forma basis rolling 12 months, ADDvise expects to reach revenue of SEK 1 billion with an…